CN102149700A - 作为金属螯合剂的脱氮杂去铁硫辛聚醚类似物的新型盐和多晶型物 - Google Patents

作为金属螯合剂的脱氮杂去铁硫辛聚醚类似物的新型盐和多晶型物 Download PDF

Info

Publication number
CN102149700A
CN102149700A CN2009801359235A CN200980135923A CN102149700A CN 102149700 A CN102149700 A CN 102149700A CN 2009801359235 A CN2009801359235 A CN 2009801359235A CN 200980135923 A CN200980135923 A CN 200980135923A CN 102149700 A CN102149700 A CN 102149700A
Authority
CN
China
Prior art keywords
solid composition
salt
polymorph
magnesium
dadft
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801359235A
Other languages
English (en)
Chinese (zh)
Inventor
A·E·塔珀
H·Y·林霍夫
S·D·帕伦特
P·安德烈斯
J·A·汉科
H·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FerroKin BioScience Inc
Original Assignee
FerroKin BioScience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FerroKin BioScience Inc filed Critical FerroKin BioScience Inc
Priority to CN201310322314.9A priority Critical patent/CN103435569B/zh
Publication of CN102149700A publication Critical patent/CN102149700A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/10—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CN2009801359235A 2008-07-14 2009-07-14 作为金属螯合剂的脱氮杂去铁硫辛聚醚类似物的新型盐和多晶型物 Pending CN102149700A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310322314.9A CN103435569B (zh) 2008-07-14 2009-07-14 作为金属螯合剂的脱氮杂去铁硫辛聚醚类似物的新型盐和多晶型物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8057208P 2008-07-14 2008-07-14
US61/080,572 2008-07-14
US15257209P 2009-02-13 2009-02-13
US61/152,572 2009-02-13
PCT/US2009/050532 WO2010009120A2 (en) 2008-07-14 2009-07-14 Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201310322314.9A Division CN103435569B (zh) 2008-07-14 2009-07-14 作为金属螯合剂的脱氮杂去铁硫辛聚醚类似物的新型盐和多晶型物

Publications (1)

Publication Number Publication Date
CN102149700A true CN102149700A (zh) 2011-08-10

Family

ID=41550988

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2009801359235A Pending CN102149700A (zh) 2008-07-14 2009-07-14 作为金属螯合剂的脱氮杂去铁硫辛聚醚类似物的新型盐和多晶型物
CN201310322314.9A Expired - Fee Related CN103435569B (zh) 2008-07-14 2009-07-14 作为金属螯合剂的脱氮杂去铁硫辛聚醚类似物的新型盐和多晶型物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201310322314.9A Expired - Fee Related CN103435569B (zh) 2008-07-14 2009-07-14 作为金属螯合剂的脱氮杂去铁硫辛聚醚类似物的新型盐和多晶型物

Country Status (13)

Country Link
US (4) US8063227B2 (https=)
EP (1) EP2303853A4 (https=)
JP (1) JP2011528037A (https=)
KR (1) KR20110039347A (https=)
CN (2) CN102149700A (https=)
AU (1) AU2009271074B2 (https=)
CA (1) CA2728636A1 (https=)
IL (2) IL210294A (https=)
MX (1) MX2011000486A (https=)
MY (1) MY163516A (https=)
NZ (2) NZ590302A (https=)
WO (1) WO2010009120A2 (https=)
ZA (1) ZA201100311B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107708693A (zh) * 2015-04-27 2018-02-16 佛罗里达大学研究基金会 代谢程序化的金属螯合剂及其用途
US11931346B2 (en) 2011-12-16 2024-03-19 University Of Florida Research Foundation, Incorporated Uses of 4′-desferrithiocin analogs

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005034949A1 (en) * 2003-09-09 2005-04-21 University Of Florida Desferrithiocin derivatives and their use as iron chelators
TR201910900T4 (tr) 2005-04-04 2019-08-21 Univ Florida Desferritiyokin polieter analogları.
WO2008115433A1 (en) * 2007-03-15 2008-09-25 University Of Florida Desferrithiocin polyether analogues
MY163516A (en) 2008-07-14 2017-09-15 Ferrokin Biosciences Inc Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
EP2459544A4 (en) * 2009-07-27 2012-12-05 Ferrokin Biosciences Inc DESDAADESFERROTHIOCIN POLYETHERAL ANALOGUE PROGRUGS USING METAL CHLORIDE
EP2566854A4 (en) * 2010-05-04 2013-11-06 Shire Llc DESAZADESFERROTHIOCIN AND DEAZADESFERROTHIOCIN POLYETHER ANALOGS AS METAL CHELATORS
US8993606B2 (en) 2011-12-09 2015-03-31 Ferrokin Biosciences, Inc. Oral formulations for treating metal overload
EP2928469A4 (en) * 2012-12-07 2016-11-02 Ferrokin Biosciences Inc POLYMORPHIC FORMS OF DESAZADESFERRITHIOCIN ANALOGS
JP2016513652A (ja) 2013-03-15 2016-05-16 フェロキン バイオサイエンシーズ， インコーポレイテッド デスアザデスフェリチオシン類似体の多形形態
AU2014352780A1 (en) * 2013-11-22 2016-06-09 University Of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
TWI695717B (zh) * 2014-03-06 2020-06-11 美商 Ptc 治療公司 １,２,４-二唑苯甲酸之鹽及醫藥組合物
US10446309B2 (en) 2016-04-20 2019-10-15 Vishay Dale Electronics, Llc Shielded inductor and method of manufacturing
CN107119083A (zh) * 2017-04-28 2017-09-01 江苏梦得新材料科技有限公司 一种生物酶法制备聚二硫二丙烷磺酸钠的方法
CN107174917A (zh) * 2017-05-01 2017-09-19 蒋里军 粘土矿物治霾方法及其摩天大楼治霾烟囱
CN108264892A (zh) * 2017-12-21 2018-07-10 东北农业大学 一种用于释放地下油质材料的表面活性剂的组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006107626A1 (en) * 2005-04-04 2006-10-12 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083966A (en) 1998-08-31 2000-07-04 University Of Florida Thiazoline acid derivatives
AT500490A1 (de) * 2001-10-16 2006-01-15 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von substituierten thiazolinen und deren zwischenprodukte
US20040132789A1 (en) * 2002-08-22 2004-07-08 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
JPWO2004031163A1 (ja) * 2002-10-01 2006-02-02 株式会社カネカ 光学活性α−置換システインまたはその塩の製造方法並びにその合成中間体及びその製造方法
JP2007505044A (ja) 2003-09-09 2007-03-08 ユニバーシティ オブ フロリダ リサーチ ファウンデイション、インコーポレイテッド ポリアミン−金属キレーター接合体
WO2005034949A1 (en) 2003-09-09 2005-04-21 University Of Florida Desferrithiocin derivatives and their use as iron chelators
US20080138440A1 (en) * 2006-11-29 2008-06-12 Cormedix Inc. Methods of diagnosing and alleviating gadolinium toxicity
EP2101764A4 (en) 2006-12-12 2010-02-17 Univ Florida ACTINIDE DECORATION AGENT WITH DESFERRITHIOCIN ANALOGON
WO2008115433A1 (en) * 2007-03-15 2008-09-25 University Of Florida Desferrithiocin polyether analogues
MY163516A (en) 2008-07-14 2017-09-15 Ferrokin Biosciences Inc Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
EP2459544A4 (en) 2009-07-27 2012-12-05 Ferrokin Biosciences Inc DESDAADESFERROTHIOCIN POLYETHERAL ANALOGUE PROGRUGS USING METAL CHLORIDE
WO2011028255A2 (en) 2009-08-25 2011-03-10 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues and uses thereof
EP2566854A4 (en) 2010-05-04 2013-11-06 Shire Llc DESAZADESFERROTHIOCIN AND DEAZADESFERROTHIOCIN POLYETHER ANALOGS AS METAL CHELATORS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006107626A1 (en) * 2005-04-04 2006-10-12 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
RAYMOND J. BERGERON，等: "Impact of the 3,6,9-Trioxadecyloxy Group on Desazadesferrithiocin Analogue Iron Clearance and Organ Distribution", 《JOURNAL OF MEDICINAL CHEMISTRY》 *
RAYMOND J.BERGERON，等: "(S)-4,5-Dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers:a solution to nephrotoxicity", 《JOURNAL OF MEDICINAL CHEMISTRY》 *
庞怡诺，等: "药物多晶型", 《华西药学杂志》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11931346B2 (en) 2011-12-16 2024-03-19 University Of Florida Research Foundation, Incorporated Uses of 4′-desferrithiocin analogs
CN107708693A (zh) * 2015-04-27 2018-02-16 佛罗里达大学研究基金会 代谢程序化的金属螯合剂及其用途

Also Published As

Publication number Publication date
US20120270911A1 (en) 2012-10-25
US8063227B2 (en) 2011-11-22
EP2303853A4 (en) 2011-08-10
CN103435569B (zh) 2015-08-19
NZ590302A (en) 2013-02-22
WO2010009120A8 (en) 2011-02-24
CA2728636A1 (en) 2010-01-21
US8829197B2 (en) 2014-09-09
NZ605452A (en) 2014-05-30
ZA201100311B (en) 2011-12-28
IL210294A0 (en) 2011-03-31
AU2009271074A1 (en) 2010-01-21
MX2011000486A (es) 2011-08-03
AU2009271074B2 (en) 2014-10-30
IL210294A (en) 2014-04-30
US8710087B2 (en) 2014-04-29
US8846731B2 (en) 2014-09-30
EP2303853A2 (en) 2011-04-06
US20110160257A1 (en) 2011-06-30
US20100137383A1 (en) 2010-06-03
KR20110039347A (ko) 2011-04-15
IL231558A0 (en) 2014-04-30
WO2010009120A2 (en) 2010-01-21
CN103435569A (zh) 2013-12-11
WO2010009120A3 (en) 2010-04-22
JP2011528037A (ja) 2011-11-10
MY163516A (en) 2017-09-15
US20120202857A1 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
CN102149700A (zh) 作为金属螯合剂的脱氮杂去铁硫辛聚醚类似物的新型盐和多晶型物
US9045440B2 (en) Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents
CN102648189A (zh) 作为金属螯合剂的脱氮杂去铁硫辛聚醚类似物的前药
WO2013096816A1 (en) Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
EP4419504A1 (en) Kdm1a inhibitors for the treatment of disease
WO2019246454A1 (en) Method of treating a condition associated with neurodegeneration using inhibitors of oat3
AU2013205485A1 (en) Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
AU2014361790B2 (en) Polymorphic and amorphous forms of cortisol 17-alpha-benzoate and methods for the preparation and use thereof
HK1172335A (en) Prodrugs of desazadesferrothiocin polyether analogues as metal chelation agents
US20150299151A1 (en) Polymorph forms of desazadesferrithiocin analogs
JP2016513652A (ja) デスアザデスフェリチオシン類似体の多形形態

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110810